Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (EPIlepsy Cell therapy) trial as the primary basis for ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...